UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 80,221 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 21.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 287,911 shares of the company's stock after selling 80,221 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.48% of Protagonist Therapeutics worth $11,113,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the stock. Farallon Capital Management LLC boosted its position in shares of Protagonist Therapeutics by 1.2% during the 4th quarter. Farallon Capital Management LLC now owns 5,930,006 shares of the company's stock valued at $228,898,000 after purchasing an additional 69,000 shares in the last quarter. RTW Investments LP boosted its holdings in Protagonist Therapeutics by 1.3% during the fourth quarter. RTW Investments LP now owns 5,498,545 shares of the company's stock worth $212,244,000 after buying an additional 72,433 shares in the last quarter. BVF Inc. IL grew its position in Protagonist Therapeutics by 2.7% in the fourth quarter. BVF Inc. IL now owns 1,900,015 shares of the company's stock worth $73,341,000 after buying an additional 49,848 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Protagonist Therapeutics by 6.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,392,652 shares of the company's stock valued at $53,758,000 after buying an additional 83,185 shares in the last quarter. Finally, Deep Track Capital LP acquired a new stake in shares of Protagonist Therapeutics during the 4th quarter valued at $38,600,000. Institutional investors and hedge funds own 98.63% of the company's stock.

Protagonist Therapeutics Trading Up 0.9%

PTGX traded up $0.47 during trading on Wednesday, hitting $51.53. The stock had a trading volume of 693,302 shares, compared to its average volume of 891,886. Protagonist Therapeutics, Inc. has a 12 month low of $28.96 and a 12 month high of $60.60. The firm has a market cap of $3.19 billion, a PE ratio of 19.37 and a beta of 2.65. The company has a 50 day simple moving average of $45.34 and a 200-day simple moving average of $42.81.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The firm had revenue of $28.32 million for the quarter, compared to analyst estimates of $30.44 million. As a group, sell-side analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Insider Buying and Selling at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 24,903 shares of Protagonist Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the completion of the sale, the chief financial officer now owns 62,821 shares of the company's stock, valued at approximately $3,689,477.33. The trade was a 28.39% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Arturo Md Molina sold 30,514 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $55.74, for a total value of $1,700,850.36. Following the completion of the sale, the insider now directly owns 83,892 shares of the company's stock, valued at approximately $4,676,140.08. This trade represents a 26.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 61,173 shares of company stock valued at $3,461,180 in the last 90 days. 4.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently issued reports on PTGX. Wedbush restated an "outperform" rating and issued a $70.00 target price on shares of Protagonist Therapeutics in a report on Friday, March 28th. JPMorgan Chase & Co. lifted their price target on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. JMP Securities reaffirmed a "market outperform" rating and set a $58.00 price objective on shares of Protagonist Therapeutics in a research note on Friday, February 7th. BMO Capital Markets raised their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Protagonist Therapeutics has an average rating of "Moderate Buy" and an average price target of $65.44.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.